Cookson J, Silverstone T, Wells B
Acta Psychiatr Scand. 1981 Nov;64(5):381-97. doi: 10.1111/j.1600-0447.1981.tb00797.x.
Pimozide (PMZ), a relatively specific dopamine (DA) receptor blocking drug, was compared to chlorpromazine (CPZ) in a double-blind, between-patient clinical trial in mania. The trial lasted 14 days. Twenty-three patients who fulfilled Feighner's criteria for mania entered the trial (one patient entering on two separate occasions). Both drugs led to clinical improvement, with a significant effect being noted within 24 hours. According to one of the two rating scales used, initial improvement was greater with chlorpromazine, probably due to its greater sedative effect. By 7 days both drugs were equally effective. Sedative side effects were more frequent in patients on CPZ; extrapyramidal side effects were more frequent with PMZ. The finding that the relatively specific DA receptor blocking drug PMZ was as effective as CPZ in the treatment of mania is consistent with the view that hyperactivity of central DA pathways is involved in the pathogenesis of this condition.
匹莫齐特（PMZ）是一种相对特异性的多巴胺（DA）受体阻断药物，在一项针对躁狂症患者的双盲、患者间临床试验中，将其与氯丙嗪（CPZ）进行了比较。该试验持续了14天。23名符合费格纳躁狂症标准的患者进入试验（一名患者分两次进入试验）。两种药物均使临床症状改善，在24小时内即观察到显著效果。根据所使用的两种评分量表之一，氯丙嗪的初始改善效果更佳，这可能归因于其更强的镇静作用。到第7天时，两种药物的效果相当。服用CPZ的患者出现镇静副作用的频率更高；服用PMZ的患者出现锥体外系副作用的频率更高。相对特异性的DA受体阻断药物PMZ在治疗躁狂症方面与CPZ效果相当这一发现，与中枢DA通路功能亢进参与该病症发病机制的观点一致。
